Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Acta Clin Croat ; 56(1): 133-142, 2017 03.
Article in English | MEDLINE | ID: mdl-29120551

ABSTRACT

The purpose of this review is to analyze current medical strategies in the prevention of ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation for in vitro fertilization. Owing to contemporary preventive measures of OHSS, the incidence of moderate and severe forms of the syndrome varies between 0.18% and 1.40%. Although none of medical strategies is completely effective, there is high-quality evidence that replacing human chorionic gonadotropin (hCG) by gonadotropin-releasing hormone (GnRH) agonists after GnRH antagonists and moderate- quality evidence that GnRH antagonist protocols, dopamine agonists and mild protocols reduce the occurrence of OHSS. Among various GnRH agonists, buserelin 0.5 mg, triptorelin 0.2 mg and leuprolide acetate (0.5-4 mg) have been mostly utilized. Although GnRH trigger is currently regarded as the best tool for OHSS prevention, intensive luteal support with exogenous administration of estradiol and progesterone or low-dose hCG on the day of oocyte retrieval or on the day of GnRH agonist trigger are required to achieve optimal conception rates due to early luteolysis. Among currently available dopamine agonists, cabergoline, quinagolide and bromocriptine are the most common drugs that should be used for prevention of both early and late OHSS. Mild stimulation protocols offer attractive option in OHSS prevention with satisfactory pregnancy rates.


Subject(s)
Fertility Agents, Female/therapeutic use , Ovarian Hyperstimulation Syndrome/prevention & control , Ovulation Induction/methods , Aminoquinolines/therapeutic use , Bromocriptine/therapeutic use , Buserelin/therapeutic use , Cabergoline , Chorionic Gonadotropin/therapeutic use , Dopamine Agonists/therapeutic use , Ergolines/therapeutic use , Estradiol/therapeutic use , Estrogens/therapeutic use , Female , Fertilization in Vitro , Gonadotropin-Releasing Hormone/agonists , Gonadotropin-Releasing Hormone/antagonists & inhibitors , Humans , Leuprolide/therapeutic use , Oocyte Retrieval , Pregnancy , Pregnancy Rate , Progesterone/therapeutic use , Progestins/therapeutic use , Triptorelin Pamoate/therapeutic use
2.
Gynecol Endocrinol ; 32(12): 937-941, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27426425

ABSTRACT

Young men comprise the overwhelming majority of men with spinal cord injury (SCI), the incidence of which has been growing over the years. Due to advances in physical medicine and rehabilitation, remarkable improvements in survival rates have been reported, leading to life expectancies similar to those of the general population. However, many sexual and reproductive functions may be impaired due to erectile or ejaculatory dysfunction and semen abnormalities, characterised by low-sperm motility or viability in SCI males who have not become parents yet. Nevertheless, fatherhood is still possible through the introduction of specialised medical management, by using various medical, technical and surgical methods for sperm retrieval in combination with assisted reproductive techniques. Erectile dysfunction can be managed by the use of phosphodiesterase-5 inhibitors, intracavernosal injections, vacuum devices and penile prostheses. Semen can be obtained from the vast majority of anejaculatory men by medically assisted ejaculation through the use of penile vibratory stimulation or electroejaculation and via prostate massage or surgical procedures. Despite impaired sperm parameters, reasonable pregnancy rates similar to those in able-bodied subfertile cohorts have been reported. However, future research should focus on the optimisation of semen quality in these men and on improving natural ejaculation.


Subject(s)
Infertility, Male/rehabilitation , Reproductive Techniques, Assisted , Sexual Dysfunction, Physiological/rehabilitation , Spinal Cord Injuries/complications , Humans , Infertility, Male/etiology , Male , Sexual Dysfunction, Physiological/etiology
3.
Coll Antropol ; 40(3): 211-8, 2016 Sep.
Article in English | MEDLINE | ID: mdl-29139641

ABSTRACT

Sex hormone binding globulin (SHBG) is an important protein, not only for transporting sex steroids which is its primary role, but with the discovery of a specific receptor that binds SHBG, a novel approach regarding classic 'free-hormone hypothesis' should be implemented. Research in SHBG gene and it expression has been done, as well as cellular signaling that controls it. It provides significant knowledge of the impact of certain well ­defined cellular level signaling pathways and how they affect the level of SHBG production. Moreover, new insights have proven that SHBG isn't just a peripherally synthesized protein. Its origin has been proven to exist in the brain, namely in the hypothalamus and the pituitary, where it is spatially closely related to oxytocin-producing neurons. The main peripheral organ that produces SHBG is the liver. Since the liver is the central metabolic organ, certain metabolic diseases will result in changed SHBG serum levels. On the other hand, endocrine disorders that affect tissues involved in sex hormone regulation will also have an impact on SHBG levels. Thusly, SHBG stands as one of the mediators between various endocrine tissues and definitely contributes with its own pathophysiological role in diseases such as: obesity, metabolic syndrome, polycystic ovary syndrome, osteoporosis, breast and prostate cancer. Its value expands to the area of clinical medicine as a marker of certain pathological states. Some studies already established its reliability and the growing trend to implement it as a useful clinical marker is present. It still remains largely understudied, from physiological and clinical aspect, but recent findings give notions that SHBG plays an important role in health and disease and could be a useful assessment marker.


Subject(s)
Biomarkers/blood , Sex Hormone-Binding Globulin/analysis , Female , Humans , Male , Sex Hormone-Binding Globulin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...